Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

Keyphrases

• Population-based 100%
• Patient Cohort 100%
• Overall Survival 100%
• Metastatic Melanoma 100%
• Large Population 100%
• Anti-PD-1 100%
• Immune Checkpoint Inhibitors 100%
• Prognostic Biomarker 75%
• Checkpoint Inhibitors 75%
• Treatment Efficacy 50%
• Young Patients 50%
• Age-related 50%
• Progression-free Survival 50%
• Immune Dysfunction 50%
• Ipilimumab 50%
• Pembrolizumab 50%
• High Risk 25%
• Comorbidity 25%
• Multivariate Analysis 25%
• Elderly People 25%
• Elderly Patients 25%
• Survival Rate 25%
• Older Patients 25%
• Age-related Changes 25%
• National Cohort 25%
• Age Impact 25%
• Drug Target 25%
• High Survival 25%
• Serious Outcomes 25%
• Immune-related Adverse Events 25%

Biochemistry, Genetics and Molecular Biology

• Overall Survival 100%
• Immune Checkpoints 100%
• Progression Free Survival 66%
• Ipilimumab 66%
• Pembrolizumab 66%
• Comorbidity 33%
• Multivariate Analysis 33%
• Survival Rate 33%
• Drug Targeting 33%